Teva 4Q Revenues: $5.7 billion (+28%) 4Q Earnings: $505.0 million (-35%) FY Revenues: $18.3 billion (+14%) FY Earnings: $2.8 billion (-17%) Comments: U.S. revenues in the quarter were $3.0 billion (+32%), accounting for 54% of total revenues, bolstered by Cephalon sales and branded product revenues, offset by lower generic sales. Revenues in Europe were $1.5 billion (+13%), accounting for 26% of total revenues, due to stronger generic and branded product revenues primarily in Italy and Spai...